Latest Content

Adding Anktiva to BCG led to better responses than BCG alone in people with high-risk bladder cancer who had not yet received BCG, the company said.

An Ohio State hematologist explains how she weighs chemotherapy against targeted drugs, what side effects patients should expect and why learning about this specific leukemia matters.

Leanne Citrone shares how a BRCA mutation, an elective mastectomy and a stage 2C ovarian cancer diagnosis shaped her outlook, anxiety and advice to others.

A colon cancer survivor who cared for her mother with lung cancer shares how she learned to speak up, plus tips for advocating for yourself or a loved one.

Medicare's Part D out-of-pocket cap rises to $2,400 in 2027. Here is what that means for people taking costly oral cancer drugs, how the monthly payment plan works with it and what to check before open enrollment ends Dec. 7.

Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.

Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.

A once-daily oral pill gives patients with symptomatic TGCT another option when surgery could cause more harm than good.

For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.

Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.

Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.

Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.

In a study of 8,259 rural Medicare patients with advanced non-small cell lung cancer diagnosed from 2014 to 2019, only 35.9% had tumor gene testing, and those who were tested were more likely to get targeted therapy.